Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIND Biosciences Inc.

This article was originally published in Start Up

Executive Summary

BIND Biosciences generates nanoparticles with unique targeting agents that allow them to home in on cancerous cells with deadly precision. Because it's impossible to mathematically design the optimal particle, BIND scientists have created large combinatorial libraries of nanoparticles with different biophysical and chemical properties.

You may also be interested in...



In Oncology Drug Boom, Can Next-Gen Cytotoxics Fit In?

The drug industry has placed a bull's eye on the field of oncology as a key therapeutic area, but not all oncology players are created equal.

FDA Seeks Public Input To Develop Guidance For Nanotechnology In Pharmaceuticals

Sept. 8 public meeting requests input on safety, efficacy points to consider for using nanotech in drugs, biologics.

TransGenex Nanobiotech Inc.

TransGenex Nanobiotech is taking a multi-pronged approach to building a nanotechnology company. In the short term, the company is generating revenue from sales of its custom nanoparticles and its Nanogene reagents that can be used to deliver genes to cells. It is also using its technology to develop diagnostic platforms, especially for lung and ovarian cancer. Finally, TransGenex plans to develop its own novel drug candidates. It's focusing first on products with anti-inflammatory properties, which could find application in asthma as well as several cancers.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091562

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel